JP2020503017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503017A5 JP2020503017A5 JP2019533110A JP2019533110A JP2020503017A5 JP 2020503017 A5 JP2020503017 A5 JP 2020503017A5 JP 2019533110 A JP2019533110 A JP 2019533110A JP 2019533110 A JP2019533110 A JP 2019533110A JP 2020503017 A5 JP2020503017 A5 JP 2020503017A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- compound according
- nucleoside
- crrna
- modified crrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662439828P | 2016-12-28 | 2016-12-28 | |
| US62/439,828 | 2016-12-28 | ||
| US201762491818P | 2017-04-28 | 2017-04-28 | |
| US62/491,818 | 2017-04-28 | ||
| US201762572361P | 2017-10-13 | 2017-10-13 | |
| US62/572,361 | 2017-10-13 | ||
| PCT/US2017/068642 WO2018125964A1 (en) | 2016-12-28 | 2017-12-28 | Modified crispr rna and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020503017A JP2020503017A (ja) | 2020-01-30 |
| JP2020503017A5 true JP2020503017A5 (enExample) | 2021-02-12 |
Family
ID=62710685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533110A Pending JP2020503017A (ja) | 2016-12-28 | 2017-12-28 | 修飾ｃｒｉｓｐｒ ｒｎａ及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190382751A1 (enExample) |
| EP (1) | EP3562942A4 (enExample) |
| JP (1) | JP2020503017A (enExample) |
| AU (1) | AU2017388379A1 (enExample) |
| CA (1) | CA3047330A1 (enExample) |
| WO (1) | WO2018125964A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| EP3983536A4 (en) * | 2019-06-14 | 2023-11-29 | Arbor Biotechnologies, Inc. | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS |
| CA3198905A1 (en) * | 2020-10-19 | 2022-04-28 | Caribou Biosciences, Inc. | Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same |
| US20250325698A1 (en) * | 2022-04-13 | 2025-10-23 | Caribou Biosciences, Inc. | Therapeutic applications of crispr type v systems |
| JP2026523341A (ja) | 2023-05-15 | 2026-07-14 | エヌクロマ・バイオ，インコーポレーテッド | Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法 |
| CN116732075B (zh) * | 2023-06-09 | 2024-03-08 | 江南大学 | 一种生产2′-岩藻糖基乳糖的多层动态调控系统及其应用 |
| WO2025212120A1 (en) * | 2024-04-05 | 2025-10-09 | Arbor Biotechnologies, Inc. | Chemical modifications of guide rnas for crispr nucleases |
| WO2025231432A1 (en) * | 2024-05-03 | 2025-11-06 | Caribou Biosciences, Inc. | In vivo gene editing with crispr systems |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105408483A (zh) * | 2013-03-15 | 2016-03-16 | 通用医疗公司 | 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向 |
| WO2015200555A2 (en) * | 2014-06-25 | 2015-12-30 | Caribou Biosciences, Inc. | Rna modification to engineer cas9 activity |
| CA2969619A1 (en) * | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| AU2016211517B2 (en) * | 2015-01-28 | 2021-05-13 | Caribou Biosciences, Inc. | CRISPR hybrid DNA/RNA polynucleotides and methods of use |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| JP2018519811A (ja) * | 2015-06-29 | 2018-07-26 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 修飾ｃｒｉｓｐｒ ｒｎａ及び修飾単一ｃｒｉｓｐｒ ｒｎａならびにその使用 |
| WO2017181107A2 (en) * | 2016-04-16 | 2017-10-19 | Ohio State Innovation Foundation | Modified cpf1 mrna, modified guide rna, and uses thereof |
| CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
| CA3044101A1 (en) * | 2016-11-22 | 2018-05-31 | Integrated Dna Technologies, Inc. | Crispr/cpf1 systems and methods |
-
2017
- 2017-12-28 AU AU2017388379A patent/AU2017388379A1/en not_active Abandoned
- 2017-12-28 US US16/470,464 patent/US20190382751A1/en not_active Abandoned
- 2017-12-28 JP JP2019533110A patent/JP2020503017A/ja active Pending
- 2017-12-28 WO PCT/US2017/068642 patent/WO2018125964A1/en not_active Ceased
- 2017-12-28 CA CA3047330A patent/CA3047330A1/en not_active Abandoned
- 2017-12-28 EP EP17886910.3A patent/EP3562942A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506889A5 (enExample) | ||
| JP2009524696A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2021512629A5 (enExample) | ||
| JP2020022483A5 (enExample) | ||
| TW202043249A (zh) | 編輯rna的方法和組合物 | |
| JP2019517268A5 (enExample) | ||
| JP2019511491A5 (enExample) | ||
| WO2007143316A3 (en) | Compounds and methods for modulating expression of sglt2 | |
| JP2020532961A5 (enExample) | ||
| JP2016520312A5 (enExample) | ||
| JP2020500929A5 (enExample) | ||
| JP2009102380A5 (ja) | ｄｓＲＮＡを含む、ウイルス感染又は望ましくない細胞増殖によって媒介されるか又は誘導される病気又は疾患の治療用組成物 | |
| TW202028466A (zh) | 編輯RNAs的方法以及組成物 | |
| BR112021008953A2 (pt) | partículas de ácido nucleico-lipídio e de ácido-lipídio, composições, métodos para introduzir um ácido nucleico em uma célula, para distribuição in vivo de um ácido nucleico, para tratar uma doença ou um distúrbio e para preparar um composto, usos de uma partícula, compostos e nanopartícula de lipídio | |
| JP2018510621A5 (enExample) | ||
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2007509040A5 (enExample) | ||
| CY1118963T1 (el) | Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου | |
| JP6158833B2 (ja) | ベータ−カテニン関連疾患を処置するための有機組成物 | |
| JP2013535212A5 (enExample) | ||
| JP2016523087A5 (enExample) | ||
| JP2018523668A5 (enExample) | ||
| WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
| JP2009532044A5 (enExample) |